Vaccines against Botulism
AbstractBotulinum neurotoxins (BoNT) cause the flaccid paralysis of botulism by inhibiting the release of acetylcholine from motor neurons. There are seven serotypes of BoNT (A-G), with limited therapies, and no FDA approved vaccine for botulism. An investigational formalin-inactivated penta-serotype-BoNT/A-E toxoid vaccine was used to vaccinate people who are at high risk of contracting botulism. However, this formalin-inactivated penta-serotype-BoNT/A-E toxoid vaccine was losing potency and was discontinued. This article reviews the different vaccines being developed to replace the discontinued toxoid vaccine. These vaccines include DNA-based, viral vector-based, and recombinant protein-based vaccines. DNA-based vaccines include plasmids or viral vectors containing the gene encoding one of the BoNT heavy chain receptor binding domains (HC). Viral vectors reviewed are adenovirus, influenza virus, rabies virus, Semliki Forest virus, and Venezuelan Equine Encephalitis virus. Among the potential recombinant protein vaccines reviewed are HC, light chain-heavy chain translocation domain, and chemically or genetically inactivated holotoxin. View Full-Text
Share & Cite This Article
Sundeen, G.; Barbieri, J.T. Vaccines against Botulism. Toxins 2017, 9, 268.
Sundeen G, Barbieri JT. Vaccines against Botulism. Toxins. 2017; 9(9):268.Chicago/Turabian Style
Sundeen, Grace; Barbieri, Joseph T. 2017. "Vaccines against Botulism." Toxins 9, no. 9: 268.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.